Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980520 | 0.83 | AR (0.39) | — | |
| SCHEMBL21569527 | 0.82 | CSNK2A2 (0.33) | — | |
| SCHEMBL21569518 | 0.82 | GPR17 (0.34) | GPR17 | |
| SCHEMBL21569499 | 0.81 | CSNK2A2 (0.33) | — | |
| SCHEMBL26977898 | 0.81 | GPR84 (0.30) | — | |
| SCHEMBL23641446 | 0.78 | TRPV4 (0.34) | — | |
| SCHEMBL30723536 | 0.78 | TRPV4 (0.34) | — | |
| SCHEMBL27035946 | 0.77 | TRPV4 (0.33) | — | |
| SCHEMBL20355028 | 0.77 | DYRK1A (0.47) | — | |
| SCHEMBL21569544 | 0.75 | TNF (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250188061-A1 | NOVEL DEUTERATED PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2024042147-A2 | NOVEL DEUTERATED PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-29 | — | — | WO | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4298092-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| CN-116829550-A | Pyrimidine-2-ylsulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022180136-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188061-A1 | NOVEL DEUTERATED PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | DDX41, CDK2, CCNT2 | GPR17 1413/4885 |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | GPR17 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.